The move, reported by Ritzau news agency, comes after Denmark became the first country to stop using AstraZeneca's vaccine altogether over a potential link to a rare but serious form of blood clot.
The decision pushed back the scheduled conclusion of Denmark's vaccination scheme to early August from July 25.
Results of investigations into the AstraZeneca-associated blood clots "showed real and serious side-effects," Danish health agency head Soren Brostrom said when announcing the decision.
"We have therefore chosen to continue the vaccination programme for all target groups without this vaccine."
Astrazeneca said it respected Denmark's choice and would continue to provide it with data to inform future decisions.
"Implementation and rollout of the vaccine programme is a matter for each country to decide, based on local conditions," the company said.
Many countries in Europe and elsewhere have resumed using the shot, with some restricting it to certain age groups, mostly those aged above 50 or above 60.
Denmark was the first country to initially suspend all use of the AstraZeneca vaccine in March over safety concerns.
Almost one million of the country's 5.8 million population have received their first shots, 77% getting Pfizer-BioNTech's vaccine, 7.8% Moderna's and 15.3% AstraZeneca's.
Denmark is in the process of easing restrictions after its daily COVID-19 infection rate slowed to 500-600 from several thousand in December.